HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Aclaris Therapeutics (NASDAQ:ACRS) but has significantly lowered the price target from $43 to $9.
November 14, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aclaris Therapeutics' price target was reduced from $43 to $9 by HC Wainwright & Co., although the Buy rating was maintained.
The substantial reduction in price target from $43 to $9, despite maintaining a Buy rating, could shake investor confidence and lead to a short-term negative impact on Aclaris Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100